Literature DB >> 14971818

Endoscopic balloon dilatation is a safe method in the management of common bile duct stones.

C K Lin1, K H Lai, H H Chan, W L Tsai, E M Wang, M C Wei, M T Fu, C C Lo, P I Hsu, G H Lo.   

Abstract

BACKGROUNDS AND AIMS: Endoscopic sphincterotomy is a widely accepted treatment for patients with common bile duct stones. Despite improvement in this technique, endoscopic sphincterotomy is still associated with some biliary complications. Endoscopic balloon dilatation is a less traumatic and sphincter preserving method for removal of common bile duct stones. However, the results of controlled studies in comparison with these two methods are contradictory. The aim of this study is to compare the safety and efficacy of endoscopic balloon dilatation and endoscopic sphincterotomy in Chinese patients. PATIENTS AND METHODS: A total of 104 patients with common bile duct stones on endoscopic retrograde cholangiopancreatography were enrolled. They were randomly assigned to endoscopic balloon dilatation or endoscopic sphincterotomy. Endoscopic balloon dilatation was performed by using a balloon dilator to dilate the sphincter for 5 min. The common bile duct stones were then removed by a Dormia basket after endoscopic balloon dilatation or endoscopic sphincterotomy. Mechanical lithotripsy was performed if the stones were difficult to remove by Dormia basket. After discharge, patients were regularly followed up for biliary complications.
RESULTS: The successful bile duct stone clearance rate was 94.1% in endoscopic balloon dilatation group and 100% in endoscopic sphincterotomy group. Post-procedural significant haemorrhage was higher in endoscopic sphincterotomy group than in endoscopic balloon dilatation group (14/53 versus 1/48, P < 0.001). The bleeding patient from endoscopic balloon dilatation group was a case of uremia and bleeding occurred 48 h after endoscopic balloon dilatation. All the patients with post-procedural haemorrhage were controlled endoscopically. The post-procedural serum amylase level showed no significant difference in both groups and none of them developed clinical pancreatitis. After a mean 16 months follow-up, three patients (6.3%) in endoscopic balloon dilatation group and four patients (7.5%) in endoscopic sphincterotomy group developed recurrent common bile duct stones. The recurrent common bile duct stones were multiple and muddy in consistency. They were successfully removed endoscopically.
CONCLUSION: Both endoscopic balloon dilatation and endoscopic sphincterotomy are safe and effective techniques for the treatment of common bile duct stones. Endoscopic balloon dilatation can be safely applied in patients with coagulopathy and does not increase the incidence of pancreatitis or bleeding.

Entities:  

Mesh:

Year:  2004        PMID: 14971818     DOI: 10.1016/j.dld.2003.09.014

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  29 in total

1.  Dilation-assisted stone extraction: an alternative method for removal of common bile duct stones.

Authors:  Guodong Li; Qiuping Pang; Xiujuan Zhang; Haiyan Dong; Rong Guo; Hailan Zhai; Yanchun Dong; Xinyong Jia
Journal:  Dig Dis Sci       Date:  2013-11-20       Impact factor: 3.199

2.  Prevention of pancreatitis after papillary balloon dilatation by nasobiliary drainage: a randomized controlled trial.

Authors:  Xiao-Dan Xu; Jian-Jun Dai; Jian-Qing Qian; Wei-Jun Wang
Journal:  Dig Dis Sci       Date:  2014-10-17       Impact factor: 3.199

3.  Small sphincterotomy combined with endoscopic papillary large balloon dilation vs sphincterotomy alone for removal of common bile duct stones.

Authors:  Shi-Bin Guo; Hua Meng; Zhi-Jun Duan; Chun-Yan Li
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

4.  Comparison of endoscopic papillary large balloon dilation and endoscopic sphincterotomy for retrieval of choledocholithiasis: a meta-analysis of randomized controlled trials.

Authors:  Yadong Feng; Hong Zhu; Xiaoxing Chen; Shunfu Xu; Wenfang Cheng; Jinliang Ni; Ruihua Shi
Journal:  J Gastroenterol       Date:  2012-02-24       Impact factor: 7.527

5.  Endoscopic papillary balloon intermittent dilatation and endoscopic sphincterotomy for bile duct stones.

Authors:  Bai-Qing Fu; Ya-Ping Xu; Li-Sheng Tao; Jun Yao; Chun-Suo Zhou
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

Review 6.  Comparison of endoscopic papillary balloon dilatation and endoscopic sphincterotomy for bile duct stones.

Authors:  Yuji Sakai; Toshio Tsuyuguchi; Harutoshi Sugiyama; Masahiro Hayashi; Jun-Ichi Senoo; Yuko Kusakabe; Shin Yasui; Rintaro Mikata; Osamu Yokosuka
Journal:  World J Gastrointest Endosc       Date:  2016-05-25

7.  Acute biliary pancreatitis and cholecystolithiasis in a child: one time treatment with laparoendoscopic "rendez-vous" procedure.

Authors:  Gaetano La Greca; Michele Di Blasi; Francesco Barbagallo; Manuela Di Stefano; Saverio Latteri; Domenico Russello
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

Review 8.  Balloon dilation itself may not be a major determinant of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Sung Ill Jang; Gak Won Yun; Dong Ki Lee
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Factors predictive of adverse events following endoscopic papillary large balloon dilation: results from a multicenter series.

Authors:  Soo Jung Park; Jin Hong Kim; Jae Chul Hwang; Ho Gak Kim; Don Haeng Lee; Seok Jeong; Sang-Woo Cha; Young Deok Cho; Hong Ja Kim; Jong Hyeok Kim; Jong Ho Moon; Sang-Heum Park; Takao Itoi; Hiroyuki Isayama; Hirofumi Kogure; Se Joon Lee; Kyo Tae Jung; Hye Sun Lee; Todd H Baron; Dong Ki Lee
Journal:  Dig Dis Sci       Date:  2012-12-08       Impact factor: 3.199

Review 10.  Is endoscopic papillary balloon dilatation really a risk factor for post-ERCP pancreatitis?

Authors:  Toshio Fujisawa; Koichi Kagawa; Kantaro Hisatomi; Kensuke Kubota; Atsushi Nakajima; Nobuyuki Matsuhashi
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.